VCYT Q1 2024 Earnings — Veracyte, Inc. Revenue & Financial Results | Market Cap Arena

VCYTVeracyte, Inc.

$3B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$97M+17.5% YoY

Gross Profit

$62M64.5% margin

Operating Income

-$5M-4.8% margin

Net Income

-$2M-1.9% margin

EPS (Diluted)

$-0.02

QoQ Revenue Growth

-1.4%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$11M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$81M

Stockholders' Equity

$1.1B

Cash & Equivalents

$209M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$97M	$82M	+17.5%
Gross Profit	$62M	$56M	+11.2%
Operating Income	-$5M	-$10M	+55.6%
Net Income	-$2M	-$8M	+77.0%

Revenue Segments

Testing

$90M93%

Product

$4M4%

Biopharmaceutical And Other

$3M3%